<DOC>
	<DOCNO>NCT00227435</DOCNO>
	<brief_summary>This study conduct determine safety , tolerance , pharmacokinetics antiviral activity val-mCyd dos range 50 mg 800 mg per day .</brief_summary>
	<brief_title>Dose Escalation Study Evaluate Safety Antiviral Activity Val-mCyd Adults With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Documented clinical history chronic hepatitis C compensate liver disease No antiviral treatment hepatitis C 6 month prior Screening visit Other protocoldefined inclusion criterion may apply . Patient pregnant breastfeeding Patient coinfected HBV HIV Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>